文献速递肝胆胰外科胃肠外科

代偿期与再代偿期肝硬化乙肝相关肝癌肝切除术的疗效与安全性

Efficacy and safety of hepatectomy in hepatitis B-related hepatocellular carcinoma with compensated versus recompensated cirrhosis: A propensity score matching study.
PubMed 文献 · Surgery · 2026-05-20

两组术后肝失代偿、90天死亡率、肝衰竭及主要并发症均无显著差异,5年总生存率和无进展生存率亦相当,提示肝切除术对再代偿期患者是可行选择。

要点

  • 两组90天死亡率、肝衰竭及主要并发症无显著差异。
  • 5年总生存率和无进展生存率两组比较无统计学差异。

核心结论

  • 乙肝相关肝癌合并代偿期与再代偿期肝硬化患者行肝切除术的安全性和疗效相当,再代偿期是可行的手术选择。

临床怎么用

  • 对于乙肝相关肝癌合并再代偿期肝硬化的患者,肝切除术可作为可行治疗选项,但需结合多学科评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Baveno VII consensus recently defined recompensation in patients with decompensated cirrhosis. Whether hepatectomy is a viable option for recompensated patients remains uncertain. The purpose of this retrospective study was to evaluate the efficacy and safety of hepatectomy of hepatitis B-related hepatocellular carcinoma with recompensated cirrhosis. METHODS: Clinical data of patients with hepatitis B-related hepatocellular carcinoma who underwent hepatectomies between January 2011 and December 2022 were collected. Patients with cirrhosis were stratified into compensated and recompensated cohorts. Propensity score matching was used to minimize the effect of potential selection bias on the results. RESULTS: Six hundred twenty-two patients with hepatitis B-related hepatocellular carcinoma complicated with compensated cirrhosis, and 81 patients complicated with recompensated cirrhosis were enrolled in this study. After propensity score matching, 80 hepatocellular carcinoma patients with recompensated cirrhosis and 80 patients with compensated cirrhosis were matched and analyzed. Postoperative liver decompensation was comparable between the compensated group and recompensated group (P = .828). In addition, the 90-day mortality (P = .620), posthepatectomy liver failure (P = .137), and major complications (not related to hepatic dysfunction) (P = .514) were comparable between the 2 groups. The 5-year overall survival rate in the compensated and recompensated groups was 65.5% and 56.1% (P = .357), respectively. The 5-year progression-free survival rate was 50.2% in patients with compensated cirrhosis and 35.5% in patients with recompensated cirrhosis (P = .426). CONCLUSION: The safety and efficacy of hepatectomy in hepatitis B-related hepatocellular carcinoma patients with compensated cirrhosis and recompensated cirrhosis are comparable; therefore, it represents a viable treatment option for these patients.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Wu N, Zhang C, Liu Q, et al. Efficacy and safety of hepatectomy in hepatitis B-related hepatocellular carcinoma with compensated versus recompensated cirrhosis: A propensity score matching study. Surgery. 2026. PMID: 42269209. doi:10.1016/j.surg.2026.110330

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。